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The prevalence of urinary disorders such as nocturia and 
associated symptoms gradually increases with age, and has a 
great influence on the quality of life.[1,2] Elderly people with 
nocturia are at great risk for bone fracture and mortality.[3] Thus, 
prevention and treatment of urinary disorders are expected to 
improve this problem. Overactive bladder (OAB), a common 
urinary disorder, is well known and defined by the International 
Continence Society (ICS) as a syndrome with urgency, with 
or without urge incontinence, usually with frequency and 
nocturia.[1] OAB symptoms are commonly observed in patients 
with dysfunction of the lower urinary tract. Recently, the 
Overactive Bladder Symptom Score (OABSS) was developed and 
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validated by Homma et al. as a useful assessment tool specifically 
for evaluating OAB symptoms.[4] OABSS scores are based on 
answers to self‑assessed questions.
Pumpkin is an edible fruit found in the American and 
European continents and is grown in Asia and Africa. The extract 
of the seed is a rich source of vitamins, linoleic acid, oleic acid, and 
microelements. Especially, the oil extracted from Cucurbita pepo 
has been useful for the treatment of urinary disorders. In previous 
reports, the effect of the pumpkin seed oil from C. pepo has been 
investigated in clinical trials involving over 2000 men suffering 
from benign prostate hypertrophy (BPH).[5] The oil significantly 
improved their urinary dysfunction. In an animal study, 
Gossell‑Williams et al. demonstrated that oil from the pumpkin 
seed of C. pepo inhibited testosterone‑induced hyperplasia of the 
prostate of rats.[6] Rats treated with 0.3 mg/100 g body weight of 
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ABSTRACT
The pumpkin seed oil obtained from Cucurbita pepo has been shown to be useful for the treatment of nocturia in patients with urinal 
disorders in several western countries. In this study, we evaluated the effect of the pumpkin seed oil from Cucurbita maxima on urinary 
dysfunction in human overactive bladder (OAB). Forty‑five subjects were enrolled in this study. An extract of pumpkin seed oil 
from C. maxima (10 g of oil/day) was orally administrated for 12 weeks. After 6 and 12 weeks, urinary function was evaluated using 
Overactive Bladder Symptom Score (OABSS). Pumpkin seed oil from C. maxima significantly reduced the degree of OABSS in the 
subjects. The results from our study suggest that pumpkin seed oil extracts from C. maxima as well as from C. pepo are effective for 
urinary disorders such as OAB in humans.
Key words: Cucurbita maxima, Overactive bladder, Pumpkin seed oil
This is an open access article under the CC BY-NC-ND license.
Nishimura, et al. / Journal of Traditional and Complementary Medicine 4 (2014) 72‑74
73
testosterone showed an increase of prostate size ratio, but admin‑
istration of 2.0 or 4.0 mg/100 g body weight of pumpkin seed oil 
from C. pepo inhibited the prostate size ratio in rats treated with 
testosterone. These previous studies have clarified the effect of 
pumpkin seed oil extracted from C. pepo, but there has been no 
clinical investigation on urinary disorder treatment using any other 
kind of pumpkin seed oil.
In Japan, especially in Hokkaido, Cucurbita maxima is the main 
pumpkin species grown for food. Thus, numerous pumpkin seeds 
are available here. Ojiako et al. have analyzed the composition 
of seeds of C. maxima as having various fatty acids, proteins, 
carbohydrates, and minerals.[7] Recently, we have developed a 
product extracted from the pumpkin seed oil of C. maxima, and 
we herein evaluated the effect of the product on urinary disorders 
in volunteers suffering from OAB symptom.
MATERIALS AND METHODS
Subject and study design
Forty‑five volunteers (male: female = 25:20; age 41‑80 years) 
were enrolled in this study. Subjects were excluded if they were 
pregnant or had severe or acute diseases (e.g. cancer, infection, 
and acute organic failure such as heart or hepatic failure). All 
were older than 20 years of age. Ten grams of the pumpkin seed 
oil extracted from C. maxima was daily and orally administered 
in the subjects for 12 weeks. Analytical results of the composi‑
tion of the pumpkin seed oil with regard to nutrients, vitamins, 
fatty acids, and sterols are provided in Table 1. All protocols in 
this study were approved by the Ethical Committee of Hokkaido 
Information University, and written informed consent was ob‑
tained from all participating subjects. Demographic and medical 
data were obtained from the medical records and interviews at 
study entry. Blood samples were obtained in the morning after 
overnight fasting, and biochemical data concerning lipids were 
measured.
Diagnosis and evaluation of OAB
To diagnose and evaluate OAB, the subjects completed the 
OABSS questionnaire for evaluation of daytime frequency, 
nighttime frequency, urgency, and urgency incontinence, as 
described previously.[4]
Statistical analysis
Values are expressed as means ± standard deviation (SD). 
All statistical analyses were conducted using IBM SPSS Statistic 
19 (IBM, Armonk, NY, USA). The statistical differences in the 
results of OABSS were analyzed by Wilcoxon signed‑rank test, and 
those in the biochemical data were analyzed using Tukey’s multiple 
comparison test. P < 0.05 were considered statistically significant.
RESULTS
Demographic characteristics and physical and biochemical 
examination
All males enrolled in this study were not diagnosed as 
BPH in the hospital and did not receive the treatment of BPH. 
Moreover, the levels of serum prostate‑specific antigen (PSA) 
in all males were within normal range. Four subjects quit the 
entry on their own, and three subjects were excluded because of 
inadequate intake of the oil. The characteristics of the enrolled 
subjects are summarized in Table 2. Six and 12 weeks after 
the initial administration of the pumpkin seed oil, the average 
levels of high density lipoprotein‑cholesterol (HDL‑cholesterol) 
and low density lipoprotein‑cholesterol (LDL‑cholesterol) and 
triglyceride were essentially unchanged [Table 2]. There was 
no significant difference in the laboratory data between pre‑ and 
post‑administration of the pumpkin seed oil in various age and 
body weight groups [Table 2].
Improvement of OABSS in subjects given pumpkin seed oil
Serial changes of total score and sub‑scores of OABSS 
are summarized in Table 3. Six and 12 weeks after the initial 
administration of pumpkin seed oil from C. maxima, the total 
scores were significantly decreased compared to those on day 0 
[Table 3]. In detail, the scores on all parts of the questionnaire 
(daytime frequency, nighttime frequency, urgency, and urgency 
incontinence) significantly improved in the subjects administered 
pumpkin seed oil from C. maxima [Table 3].
DISCUSSION
OAB symptoms are found in more than 15% of humans aged 
40 and over, and are thought to increase with advancing age.[1] 
OABSS, a self‑assessment of OAB symptoms, is recognized 
as a standard tool for diagnosis and evaluation of the severity 
Table 1. Component of the pumpkin seed oil extracted from Cucurbita 






Vitamin D (μg) 2
Vitamin E (mg) 5.7
α‑ tocopherol (mg) 0.2
γ‑ tocopherol (mg) 5.5
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of OAB, and has been used in clinical studies.[4] Furthermore, 
OABSS is useful for determining the effect of treatment on 
urinary disorders.[8,9] In this study, we investigated the effect of 
pumpkin seed oil from C. maxima by OABSS. The OABSS was 
remarkably reduced in subjects given pumpkin seed oil extracted 
from C. maxima. The effect of pumpkin seed oil obtained from 
C. pepo has been tested in urinary disorders and this oil is 
now being developed for self‑medication in western countries. 
Friederich et al. have demonstrated that the pumpkin seed extract 
obtained from C. pepo improves abnormal urinary function in 
patients with BPH.[5] Oral administration of 500‑1000 mg/day of 
this extract for 12 weeks caused International Prostate Symptom 
Scores to decrease by 41.4%. Moreover, more than 96% of the 
patients had no undesired side effect due to treatment with the 
oil. In our study, consistent with the results of a previous study, 
there was no severe side effect caused by the pumpkin seed oil 
from C. maxima (data not shown). These results suggest that 
the seed extract from C. maxima is safe and well tolerated in 
the treatment of urinary disorders such as OAB and BPH. In 
our lab, biochemical analysis has been carried out to identify 
the molecules responsible in the pumpkin seed oil to allevi‑
ate urinary tract problems, but it remains to be elucidated to 
date. Although the molecular mechanism of the seed oil for 
improvement of urinary tract disorders is not well understood 
from the current study, based on a previous report, it is specu‑
lated that sitosterols contained in the seed oil are responsible 
to alleviate these disorders.[5] As for the study design, it was an 
open‑labeled trial because of excessive amount of oil volume 
required for encapsulation. To confirm the current results, we 
plan to perform a placebo‑controlled, double‑blind clinical trial 
when we identify the potential molecules, which would enable 
Table 2. Clinical characteristics and biochemical data
Day 0 6 weeks 12 weeks
Body mass index 24.73±2.86 24.98±2.80 24.97±2.76
Body weight (kg) 62.98±8.24 63.62±8.17 63.63±8.15
Total cholesterol (mg/dl) 207.5±29.7 211.2±28.9 216.4±29.8
HDL‑cholesterol (mg/dl) 67.9±17.7 70.6±18.0 71.8±17.9
LDL‑cholesterol (mg/dl) 127.2±30.6 126.9±29.1 131.0±27.2
Triglyceride (mg/dl) 116.8±58.9 114.7±66.5 119.9±78.5
Urea nitrogen (mg/dl) 14.7±3.5 15.0±2.7 14.6±3.4
Creatinine (mg/dl) 0.8±0.2 0.8±0.2 0.9±0.2
Table 3. Changes in obstructive bladder scoring system (OABSS) in all 
subjects given the extract of pumpkin seed oil (Cucurbita maxima)
Day 0 (0 week) 6 weeks 12 weeks
Total score 4.4±2.2 3.5±2.1* 2.7±2.2**
Q1 (daytime frequency) 0.7±0.5 0.6±0.5 0.4±0.5**
Q2 (nighttime frequency) 1.6±0.8 1.4±0.9 1.1±1.0**
Q3 (urgency) 1.5±1.2 1.1±1.1* 0.1±1.3**
Q4 (urgency incontinence) 0.7±0.9 0.4±0.7 0.3±0.6*
Values are expressed as means±SD. *P<0.05, **P<0.01 versus the level of 
OABSS on day 0, OABSS: Obstructive bladder scoring system
us to downsize the test or placebo sample volume good enough 
for encapsulation.
Although we demonstrated the beneficial effects of pumpkin 
seed oil from C. maxima, our results are limited in several ways. 
Ours was not a randomized, double‑blind, and placebo‑controlled 
study design. Recently, OABSS has been recognized as the 
standard system of evaluation in urinary function,[5] but the system 
involves evaluation by self‑assessment. Furthermore, the sample 
size in our study was small. Thus, further double‑blind, randomized 
controlled study is needed to confirm the effect of pumpkin seed 
oil obtained from C. maxima.
CONCLUSION
Although the results in our study are preliminary and further 
study is needed, our results suggest that pumpkin seed oil extracted 
from C. maxima has the potential for prevention or treatment of 
urinary disorders including OAB.
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